Laurent DerrÃ©

List of Publications by Year
in descending order

52 papers	2,359 citations	236925 25 h-index	223800 46 g-index
54 all docs	54 docs citations	54 times ranked	4041 citing authors

#	Article	IF	Citations
1	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. Journal of Clinical Investigation, 2010, 120, 157-167.	8.2	252
2	ILC2-modulated T cellâ€“to-MDSC balance is associated with bladder cancer recurrence. Journal of Clinical Investigation, 2017, 127, 2916-2929.	8.2	176
3	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
4	Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells. Journal of Immunology, 2006, 177, 3100-3107.	0.8	131
5	The multifaceted immune regulation of bladder cancer. Nature Reviews Urology, 2019, 16, 613-630.	3.8	123
6	Sensitive and frequent identification of high avidity neo-epitopeÂspecific CD8 + T cells in immunotherapy-naive ovarian cancer. Nature Communications, 2018, 9, 1092.	12.8	122
7	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
8	Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. European Journal of Immunology, 2001, 31, 2007-2015.	2.9	68
9	Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunology, 2013, 6, 393-404.	6.0	66
10	The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Current Opinion in Pharmacology, 2012, 12, 478-485.	3.5	61
11	Vaccinationâ€induced functional competence of circulating human tumorâ€specific CD8 Tâ€cells. International Journal of Cancer, 2012, 130, 2607-2617.	5.1	56
12	Expression of CD94/NKG2-A on Human T Lymphocytes Is Induced by IL-12: Implications for Adoptive Immunotherapy. Journal of Immunology, 2002, 168, 4864-4870.	0.8	55
13	Ex vivo Detectable Human CD8 T-Cell Responses to Cancer-Testis Antigens. Cancer Research, 2006, 66, 1912-1916.	0.9	55
14	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. Frontiers in Immunology, 2019, 10, 622.	4.8	55
15	Increased frequency of nonconventional double positive CD4CD8 Î±Î² T cells in human breast pleural effusions. International Journal of Cancer, 2009, 125, 374-380.	5.1	53
16	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. European Urology, 2018, 74, 540-544.	1.9	53
17	Identification of Five New HLA-B*3501-Restricted Epitopes Derived from Common Melanoma-Associated Antigens, Spontaneously Recognized by Tumor-Infiltrating Lymphocytes. Journal of Immunology, 2003, 171, 6283-6289.	0.8	50
18	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8⁺ and CD4⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope. OncoImmunology, 2016, 5, e1216290.	4.6	50

#	Article	IF	Citations
19	Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. International Journal of Cancer, 2004, 108, 863-870.	5.1	49
20	Tumor Antigenâ€“Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts. Cancer Research, 2009, 69, 8085-8093.	0.9	40
21	Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion. Oncotarget, 2016, 7, 14015-14028.	1.8	40
22	Distinct sets of Î±Î² TCRs confer similar recognition of tumor antigen NY-ESO-1‹sub›157â€“165‹/sub›by interacting with its central Met/Trp residues. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15010-15015.	7.1	39
23	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunology, Immunotherapy, 2013, 62, 747-760.	4.2	34
24	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. European Journal of Cancer, 2020, 135, 173-182.	2.8	32
25	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. PLoS ONE, 2017, 12, e0179201.	2.5	28
26	In Vivo Persistence of Codominant Human CD8+T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. Journal of Immunology, 2007, 179, 2368-2379.	0.8	26
27	Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cellâ€“Mediated Tumor Regression in the MB49 Bladder Cancer Model. Cancer Immunology Research, 2019, 7, 621-629.	3.4	26
28	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscleâ€“Invasive Bladder Cancer Patients. Clinical Cancer Research, 2017, 23, 717-725.	7.0	24
29	TCRep 3D: An Automated In Silico Approach to Study the Structural Properties of TCR Repertoires. PLoS ONE, 2011, 6, e26301.	2.5	24
30	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. European Urology, 2017, 71, 854-857.	1.9	22
31	A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide. Journal of Immunology, 2007, 179, 7635-7645.	0.8	21
32	CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. Journal of Molecular Medicine, 2013, 91, 195-205.	3.9	19
33	Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. OncoImmunology, 2017, 6, e1265720.	4.6	19
34	The pro- and anti-tumor role of ILC2s. Seminars in Immunology, 2019, 41, 101276.	5.6	19
35	Dominant Human CD8 T Cell Clonotypes Persist Simultaneously as Memory and Effector Cells in Memory Phase. Journal of Immunology, 2009, 182, 6718-6726.	0.8	18
36	IL-12 Controls Cytotoxicity of a Novel Subset of Self-Antigen-Specific Human CD28+ Cytolytic T Cells. Journal of Immunology, 2007, 178, 3566-3574.	0.8	17

#	Article	IF	Citations
37	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. OncoImmunology, 2015, 4, e1029702.	4.6	17
38	Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. International Journal of Molecular Sciences, 2020, 21, 636.	4.1	15
39	Intravaginal and Subcutaneous Immunization Induced Vaccine Specific CD8 T Cells and Tumor Regression in the Bladder. Journal of Urology, 2014, 191, 814-822.	0.4	14
40	Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer. International Journal of Molecular Sciences, 2016, 17, 1125.	4.1	14
41	Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients. OncoImmunology, 2012, 1, 694-698.	4.6	12
42	Intravaginal live attenuatedSalmonellaincreases local antitumor vaccine-specific CD8+T cells. OncoImmunology, 2013, 2, e22944.	4.6	12
43	LocalSalmonellaimmunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. OncoImmunology, 2015, 4, e1016697.	4.6	11
44	Building on a Solid Foundation: Enhancing Bacillus Calmette-GuÃ©rin Therapy. European Urology Focus, 2018, 4, 485-493.	3.1	9
45	Human primed ILCPs support endothelial activation through NF-Î²B signaling. ELife, 2021, 10, .	6.0	7
46	Immunotherapeutic strategies for bladder cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 977-981.	3.3	6
47	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. European Urology Focus, 2022, 8, 748-751.	3.1	6
48	A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling. Oncotarget, 2019, 10, 536-550.	1.8	6
49	Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer. Cancers, 2022, 14, 1135.	3.7	5
50	Siglec-7 May Limit Natural Killer Cellâ€“mediated Antitumor responses in Bladder Cancer Patients. European Urology Open Science, 2021, 34, 79-82.	0.4	5
51	Quantitative Multiparameter Assays to Measure the Effect of Adjuvants on Human Antigen-Specific CD8 T-Cell Responses. Methods in Molecular Biology, 2010, 626, 231-249.	0.9	2
52	Intramuscular Immunization Induces Antigen-specific Antibodies in Urine. European Urology Focus, 2020, 6, 280-283.	3.1	0